BRPI0410763A - derivados de triazol como inibidores de fator xa - Google Patents
derivados de triazol como inibidores de fator xaInfo
- Publication number
- BRPI0410763A BRPI0410763A BRPI0410763-2A BRPI0410763A BRPI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A BR PI0410763 A BRPI0410763 A BR PI0410763A
- Authority
- BR
- Brazil
- Prior art keywords
- factor
- compounds
- formulae
- chem
- factor viia
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"DERIVADOS DE TRIAZOL COMO INIBIDORES DE FATOR Xa". A presente invenção diz respeito aos compostos das fórmulas I e II, em que R¬ 0¬; R¬ 1¬; R¬ 2¬; R¬ 3¬; Q; J¬ 1¬; J¬ 2¬; J¬ 3¬; J¬ 4¬; J¬ 5¬; V; G e M têm os significados indicados nas reivindicações. Os compostos das fórmulas I e II são compostos farmacologicamente ativos valiosos. Eles apresentam um efeito anti-trombótico forte e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coágulo sanguíneo fator Xa (FXa) e/ou fator VIIa (FVIIa), e podem em geral ser aplicados em condições em que uma atividade indesejada de fator Xa e/ou fator VIIa está presente ou para a cura ou prevenção da qual uma inibição de fator Xa e/ou fator VIIa é intencionada. A invenção diz respeito além disso aos processos para a preparação de compostos das fórmulas I e II, seu uso, em particular como ingredientes ativos em farmacêuticos, e preparações farmacêuticas os compreendendo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011309A EP1479679A1 (en) | 2003-05-19 | 2003-05-19 | Triazole-derivatives as factor Xa inhibitors |
| PCT/EP2004/004752 WO2004101555A1 (en) | 2003-05-19 | 2004-05-05 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0410763A true BRPI0410763A (pt) | 2006-08-01 |
Family
ID=33040956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0410763-2A BRPI0410763A (pt) | 2003-05-19 | 2004-05-05 | derivados de triazol como inibidores de fator xa |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1479679A1 (pt) |
| JP (1) | JP4608495B2 (pt) |
| AT (1) | ATE394396T1 (pt) |
| AU (1) | AU2004238498B2 (pt) |
| BR (1) | BRPI0410763A (pt) |
| CA (1) | CA2526082C (pt) |
| DE (1) | DE602004013577D1 (pt) |
| IL (1) | IL171843A (pt) |
| MX (1) | MXPA05012058A (pt) |
| PE (1) | PE20050154A1 (pt) |
| TW (1) | TW200503694A (pt) |
| WO (1) | WO2004101555A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| ATE557010T1 (de) * | 2006-03-24 | 2012-05-15 | Eisai R&D Man Co Ltd | Triazolonderivat |
| SG187396A1 (en) * | 2007-07-19 | 2013-02-28 | Lundbeck & Co As H | 5-membered heterocyclic amides and related compounds |
| EP2202231A4 (en) | 2007-09-21 | 2011-09-28 | Eisai R&D Man Co Ltd | 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| EP2970141B1 (en) * | 2013-03-15 | 2020-02-26 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| ES2853483T3 (es) | 2013-03-15 | 2021-09-16 | Verseon Int Corporation | Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa |
| RS63108B1 (sr) | 2013-03-15 | 2022-04-29 | Cyclerion Therapeutics Inc | Sgc stimulatori |
| BR112017004704A2 (pt) | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
| US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| US11724997B2 (en) | 2018-03-01 | 2023-08-15 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| WO1999032454A1 (en) * | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| WO2001032628A1 (en) * | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
| AU2001273040A1 (en) * | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
-
2003
- 2003-05-19 EP EP03011309A patent/EP1479679A1/en not_active Withdrawn
-
2004
- 2004-05-05 AU AU2004238498A patent/AU2004238498B2/en not_active Ceased
- 2004-05-05 MX MXPA05012058A patent/MXPA05012058A/es active IP Right Grant
- 2004-05-05 DE DE602004013577T patent/DE602004013577D1/de not_active Expired - Lifetime
- 2004-05-05 AT AT04731152T patent/ATE394396T1/de not_active IP Right Cessation
- 2004-05-05 BR BRPI0410763-2A patent/BRPI0410763A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006529741A patent/JP4608495B2/ja not_active Expired - Fee Related
- 2004-05-05 CA CA2526082A patent/CA2526082C/en not_active Expired - Fee Related
- 2004-05-05 EP EP04731152A patent/EP1628971B1/en not_active Expired - Lifetime
- 2004-05-05 WO PCT/EP2004/004752 patent/WO2004101555A1/en not_active Ceased
- 2004-05-11 PE PE2004000482A patent/PE20050154A1/es not_active Application Discontinuation
- 2004-05-17 TW TW093113794A patent/TW200503694A/zh unknown
-
2005
- 2005-11-08 IL IL171843A patent/IL171843A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05012058A (es) | 2006-06-23 |
| EP1479679A1 (en) | 2004-11-24 |
| EP1628971A1 (en) | 2006-03-01 |
| AU2004238498B2 (en) | 2010-07-22 |
| IL171843A (en) | 2010-12-30 |
| DE602004013577D1 (de) | 2008-06-19 |
| CA2526082C (en) | 2012-07-24 |
| CA2526082A1 (en) | 2004-11-25 |
| ATE394396T1 (de) | 2008-05-15 |
| AU2004238498A1 (en) | 2004-11-25 |
| TW200503694A (en) | 2005-02-01 |
| PE20050154A1 (es) | 2005-04-29 |
| WO2004101555A1 (en) | 2004-11-25 |
| JP4608495B2 (ja) | 2011-01-12 |
| JP2006528941A (ja) | 2006-12-28 |
| EP1628971B1 (en) | 2008-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0410466A (pt) | derivados de indol como inibidores de fator xa | |
| BRPI0410430A (pt) | derivados de indazol como inibidores de fato xa | |
| PT1349847E (pt) | Novos derivados de oxibenzamidas como inibidores do factor xa | |
| WO2003044014A8 (en) | Indole-2-carboxamides as factor xa inhibitors | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| WO2005085239A3 (en) | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| NO20025810D0 (no) | Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse | |
| DK1423357T3 (da) | Urinstofderivater med antiproteolytisk aktivitet | |
| YU29702A (sh) | N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju | |
| BRPI0410763A (pt) | derivados de triazol como inibidores de fator xa | |
| WO2004050636A3 (en) | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TW200503696A (en) | Benzimidazole-derivatives as factor Xa inhibitors | |
| TNSN05296A1 (en) | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2387 DE 04-10-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |